Research for the Molecular Imaging of the PD-L1 Targeting Tracer
1 other identifier
interventional
50
1 country
1
Brief Summary
To use the molecular probe PET radionuclide (Ga-68 or F-18) WL12 peptide to detect the expression of PD-L1 in the primary and metastatic lesions in patients with solid tumor; to detect the expression heterogeneity of PD-L1 in the lesion and inter-lesions; to observe the change of PD-L1 expression in the course of treatment. To provide an approach for screening patients with high expression of PD-L1, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the Individualized antitumor treatment of targeted drugs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2019
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 6, 2019
CompletedFirst Submitted
Initial submission to the registry
March 9, 2020
CompletedFirst Posted
Study publicly available on registry
March 11, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedAugust 19, 2024
August 1, 2024
5.3 years
March 9, 2020
August 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
SUV
The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV）on PET/CT
2 years
Study Arms (1)
Imaging cohort
EXPERIMENTALAll study participants will be allocated to this arm (single-arm study).Study participants will undergo 18F-WL12 or 68Ga-WL12 PET/CT scans
Interventions
WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
Eligibility Criteria
You may qualify if:
- \. Aged \>18 years old; ECoG 0 or 1;
- \. Patients with solid tumors;
- \. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
- \. life expectancy \>=12 weeks.
You may not qualify if:
- \. Significant hepatic or renal dysfunction;
- \. Is pregnant or ready to pregnant;
- \. Cannot keep their states for half an hour;
- \. Refusal to join the clinical study;
- \. Suffering from claustrophobia or other mental diseases;
- \. Any other situation that researchers think it is not suitable to participate in the experiment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shunlian Zhou
Beijing, China
Related Publications (1)
Zhou X, Yan S, Li D, Zhu H, Liu B, Liu S, Zhao W, Yang Z, Wu N, Li N. Radiolabelled anti-PD-L1 peptide PET/CT in predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer. Ann Nucl Med. 2025 Apr;39(4):364-372. doi: 10.1007/s12149-024-02009-0. Epub 2024 Dec 14.
PMID: 39673015DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
March 9, 2020
First Posted
March 11, 2020
Study Start
August 6, 2019
Primary Completion
December 1, 2024
Study Completion
December 1, 2024
Last Updated
August 19, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share